Chronic Pain, Cortisol, and CGRP: Why Neurology Brands Migraine a Full-Brain Crisis

For generations, society has treated the migraine as a convenient excuse—a mild, one-sided headache weaponized by those looking to skip out on social obligations, school deadlines, or demanding work shifts. Patients are routinely told to “drink more water,” “step away from the screen,” or “just manage your stress,” treating a profound neurological event as a simple failure of personal discipline and lifestyle maintenance.

However, after more than 25 years of intensive clinical research, one of the world’s leading headache specialists is calling for an immediate, science-backed retirement of this stubborn cultural myth.

Dr. Messoud Ashina, a professor of neurology who heads the Center for Discoveries in Migraine at the Danish Headache Center in Copenhagen, is shifting the global conversation. His extensive body of work, recently highlighted in an interview with Illustrerad Vetenskap, proves that a migraine is not just a severe headache. It is a complex, systemic brain emergency driven by neurochemical cascades deep within the central nervous system—an unpredictable biological event that can completely incapacitate an individual for up to 72 hours.

Chronic Pain, Cortisol, and CGRP Why Neurology Brands Migraine a Full-Brain Crisis

Also Read Why a Second Opinion Might Save Your Teeth (and Money)

Deconstructing the Stereotype: “It’s Not Just a Headache”

The classic textbook definition of a migraine—a throbbing pain restricted to one side of the skull, accompanied by immediate vomiting—is vastly incomplete. Professor Ashina emphasizes that this narrow profile leaves out the true, multi-system reality of the disease, which affects roughly 14 percent of the global population according to a comprehensive epidemiological analysis published in The Lancet Neurology.

In reality, a migraine attack acts like a total sensory blackout. When an attack strikes, the brain’s sensory processing centers become completely unregulated, turning ordinary environmental stimuli into agonizing physical pain:

• Photophobia & Phonophobia: Ambient light and standard household sounds become physically intolerable, forcing individuals to isolate themselves in completely dark, silent rooms.

  Also Read The Blue Zone Morning Ritual: How Your Daily Brew Might Unlock Longevity

• The Movement Penalty: Ordinary, low-impact physical actions—such as walking across a flat floor to grab a glass of water or ascending a short flight of stairs—exponentially intensifies the throbbing intracranial pressure.

• Atypical Presentations: Contrary to old medical rules, migraine pain can present on both sides of the head simultaneously, and an individual can experience a severe, valid attack without ever experiencing nausea or vomiting.

The Mystery of Shifting Triggers: The Threshold Theory

Every migraine patient has a list of suspected “triggers”: a glass of red wine, a piece of aged cheese, a sudden weather shift, or a stressful afternoon. Yet, almost every patient has also experienced a frustrating paradox: drinking a glass of wine on Friday triggers a 3-day attack, but drinking the exact same wine the following week produces no symptoms at all.

Also Read The Hidden Imitator: Why Thyroid Disease Frequently Mimics Aging and Stress in Women

This inconsistency often leads patients to blame themselves, tracking every bite of food and habit in a state of hyper-vigilance. Professor Ashina argues that this hyper-fixation on triggers is largely misguided and harmful to a patient’s quality of life.

[High Threshold / Resilient Brain] ──> Stress + Red Wine ──> NO ATTACK
[Low Threshold / Vulnerable Brain]  ──> Stress + Red Wine ──> SYSTEMIC MIGRAINE

To explain this phenomenon, Ashina introduces the Threshold Theory. Imagine your brain possesses an internal biological “on-off” switch regulated by genetic and metabolic factors. External triggers like stress, flickering lights, or dietary choices do not directly cause the migraine on their own. Instead, they only spark an attack if your brain’s internal threshold is already dangerously low due to underlying biological shifts, such as poor sleep architecture or hormonal fluctuations like menstruation.

This threshold framework was clearly illustrated in a notable provocation study. Researchers gathered individuals who firmly believed that strenuous physical exercise or bright, flashing lights served as infallible triggers for their migraines. When subjected to these exact stressors under controlled conditions, only a small minority actually developed an attack.

The takeaway is clear: your brain’s baseline neurological vulnerability dictates the attack, not the trigger itself.

The Evolution of Treatment: From Pain Dulling to Precision Blocking

For decades, standard medical care for migraine sufferers was rudimentary. Patients were instructed to take high doses of over-the-counter painkillers and hope for the best.

The first true clinical breakthrough occurred in the early 1990s with the introduction of triptans. These medications were revolutionary because they didn’t just dull broad pain perception; they actively targeted known migraine pathways, constricting inflamed blood vessels and blocking pain signaling in the brain.

The Danger of Medication Overuse

While triptans remain an excellent tool for stopping an active attack, Ashina issues a stern warning against using them as a daily crutch. Overusing triptans or standard painkillers can trigger a secondary neurological condition known as a medication overuse headache (or rebound headache), where the frequent use of the drug actually causes the brain to become more sensitive to pain, increasing the frequency of attacks.

The Modern Era of CGRP Blockers

When a patient experiences multiple severe attacks a month, the clinical strategy must shift from treating active pain to permanent prevention. The goal is to chemically raise the brain’s internal threshold so an attack can never establish a foothold.

The current gold standard for this preventative approach centers around blocking a specific neuropeptide called CGRP (calcitonin gene-related peptide).

[Migraine Onset] ──> Surge of CGRP Neuropeptides ──> Inflams Meningeal Vessels ──> Intense Pain Signals
                                                            │
                                             [CGRP Antibody Injections Block This Pathway]

During the onset of a migraine, CGRP levels spike rapidly in the bloodstream. This peptide acts as a chemical messenger, causing the delicate blood vessels surrounding the brain to dilate and inflame while simultaneously transmitting intense pain signals back into the brainstem.

The introduction of CGRP-targeting monoclonal antibodies represents a monumental shift in neurology. These lab-made proteins, alongside smaller oral molecules called gepants, work by either binding directly to the CGRP peptide or locking onto its corresponding cellular receptor, neutralizing the pain signal before it can escalate.

Managing Expectations with Data

While CGRP therapies are highly effective—with some convenient injection forms providing continuous protection for up to four weeks—Professor Ashina maintains a realistic, data-driven perspective on their success rates.

On average, current CGRP preventive therapies succeed in cutting the total frequency of monthly migraine attacks by roughly 50 percent in just under half of the patients who try them. While this reduction represents a massive, life-altering victory for someone losing 15 days a month to a dark room, it also highlights a significant population of non-responders who require alternative therapeutic avenues.

What’s Next: The PACAP Frontier

For individuals who find no relief from CGRP inhibitors, the future of headache medicine is currently being forged in clinical trials. Professor Ashina and his colleagues are aggressively studying a secondary chemical messenger called PACAP (pituitary adenylate cyclase-activating polypeptide).

Similar to CGRP, PACAP is a natural signaling molecule capable of triggering a full-scale migraine cascade in susceptible individuals.

Currently listed on ClinicalTrials.gov are active, ongoing prevention trials evaluating an advanced PACAP-blocking monoclonal antibody designated as Lu AG09222. These studies specifically target adult populations who have failed multiple lines of traditional preventive therapies. While these PACAP-targeted medications remain in clinical testing phases, researchers expect that if human trials continue to display strong safety and efficacy profiles, these next-generation options could debut on the consumer market around 2027 or shortly thereafter.

Moving Beyond Blame: A Global Disability Crisis

The overarching message from modern neuroscience is that a migraine is a legitimate, invisible disability. It stands as one of the leading causes of years lived with disability worldwide, quietly stealing irreplaceable time from careers, classrooms, marriages, and parenting.

By validating the deep biological and genetic architecture of this condition, researchers like Professor Ashina are doing more than just inventing smarter pharmaceuticals—they are actively dismantling a centuries-old culture of patient blame. If you or someone you care about is living with this disease, stop looking for lifestyle faults. Step away from the cycle of self-reproach, consult a certified neurologist, and explore the rapidly expanding world of targeted precision therapies.

Frequently Asked Questions (FAQ)

1. Why does a migraine last up to 72 hours even if I take standard painkillers?

Because a migraine is a systemic neurological cycle, not a simple muscle tension ache. Once the neurochemical cascade begins and CGRP inflames the blood vessels and tissues surrounding the brain (the meninges), the entire central nervous system enters a state called central sensitization. During this phase, the brain remains hyper-reactive, and the cycle must naturally run its course through multiple stages until the neurochemicals return to baseline.

2. What exactly is a “medication overuse headache” and how do I avoid it?

Also known as a rebound headache, this occurs when abortive medications (like triptans, NSAIDs, or combination pain pills containing caffeine) are taken too frequently—typically more than 10 to 15 days per month. The brain adapts to the frequent presence of the drug, and when it wears off, a fresh headache is triggered. To avoid this, doctors recommend limiting acute migraine medications to no more than two days per week.

3. If triggers aren’t the primary cause of migraines, should I stop avoiding them?

You do not need to restrict your life completely trying to eliminate every hypothetical trigger. According to the Threshold Theory, a trigger only matters if your brain’s internal vulnerability threshold is already low. A smarter, more realistic strategy is to focus on broad baseline health—like maintaining a rigid sleep schedule, staying hydrated, and managing stress—which naturally keeps your threshold high, allowing your brain to tolerate occasional exposure to minor triggers without sparking an attack.

4. How are the new CGRP medications administered?

CGRP inhibitors come in a few different delivery methods. Most of the preventative monoclonal antibodies (such as Erenumab or Galcanezumab) are administered once a month via a simple, pre-filled subcutaneous injection pen that patients can safely use at home. There are also oral tablet formulations, known as gepants, which can be taken either daily for prevention or acutely to stop a sudden attack.

5. What makes the upcoming PACAP drugs different from current CGRP options?

PACAP (pituitary adenylate cyclase-activating polypeptide) is an entirely separate neurochemical pathway from CGRP. While both molecules cause blood vessel dilation and pain transmission during a migraine, they utilize completely different cellular receptors. For patients whose migraines are predominantly driven by PACAP rather than CGRP, these upcoming medications (expected around 2027) will offer a targeted solution specifically matched to their personal neurochemistry.